(Q33394138)

26 July 2017

title

Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer (English)

1 reference

26 July 2017

Shuchi S Pandya

1

1 reference

26 July 2017

James W Mier

series ordinal

2

1 reference

26 July 2017

David F McDermott

series ordinal

3

1 reference

26 July 2017

Daniel C Cho

series ordinal

4

1 reference

26 July 2017

publication date

14 February 2011

1 reference

26 July 2017

1 reference

26 July 2017

volume

108

1 reference

26 July 2017

issue

8 Pt 2

1 reference

26 July 2017

page(s)

E245-9

1 reference

26 July 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10096.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10096.X

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10096.X

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10096.X

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10096.X

Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10096.X

Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10096.X

Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10096.X

Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10096.X

Activation of stat3 in human melanoma promotes brain metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10096.X

Pathways mediating resistance to vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10096.X

Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10096.X

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10096.X

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10096.X

10.1111/J.1464-410X.2011.10096.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference